Bio-Techne announced a 4 percent year-over-year increase in fiscal Q4 revenues to $317 million, driven by growth in protein sciences and resilience in diagnostics despite some macroeconomic headwinds. While diagnostics and spatial biology revenues dipped slightly by 1 percent, protein sciences revenues grew 6 percent. The company attributed steady demand in cell therapy tools and reagents, though challenges remain in spatial biology due to NIH funding uncertainties and geopolitical factors. Bio-Techne also recently sold its Exosome Diagnostics business to MDxHealth for $15 million to strengthen its strategic focus on high-value products.